Skip to main content
. 2020 Jul 3;34(12):2830–2838. doi: 10.1111/jdv.16521

Figure 4.

Figure 4

Proportion of patients (non‐responder imputation) achieving PASI 90 responses at week 16 (a) and week 52 (b) by prior biologic treatment experience (NRI). IL‐17i, interleukin‐17 inhibitors; NRI, non‐responder imputation; PASI, Psoriasis Area and Severity Index; RZB, risankizumab; TNFi, tumour necrosis factor inhibitor; UST, ustekinumab. Data expressed as per cent of patients with 95% confidence intervals (upper bounds shown). *< 0.05, ***< 0.001 compared with ustekinumab.